SV2011003840A - Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar un paciente de acuerdo con la respuesta predicha - Google Patents
Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar un paciente de acuerdo con la respuesta predichaInfo
- Publication number
- SV2011003840A SV2011003840A SV2011003840A SV2011003840A SV2011003840A SV 2011003840 A SV2011003840 A SV 2011003840A SV 2011003840 A SV2011003840 A SV 2011003840A SV 2011003840 A SV2011003840 A SV 2011003840A SV 2011003840 A SV2011003840 A SV 2011003840A
- Authority
- SV
- El Salvador
- Prior art keywords
- methods
- response
- cells
- preach
- tumor cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Abstract
MÉTODOS PARA TRATAR PACIENTES, DICHOS MÉTODOS COMPRENDEN MÉTODOS PARA PREDECIR LAS RESPUESTAS DE LAS CÉLULAS, TALES COMO LAS CÉLULAS TUMORALES, AL TRATAMIENTO CON AGENTES TERAPÉUTICOS. ESTOS MÉTODOS INCLUYEN MEDIR, EN UNA MUESTRA DE LAS CÉLULAS, LOS NIVELES DE UNO O MÁS COMPONENTES DE UNA RED CELULAR Y DESPUÉS CALCULAR UN ESTADO DE ACTIVACIÓN DE LA RED (ÑAS) O UN ESTADO DE INHIBICIÓN DE LA RED (NIS) PARA LAS CÉLULAS USANDO UN MODELO COMPUTACIONAL DE LA RED CELULAR. LA RESPUESTA DE LAS CÉLULAS AL TRATAMIENTO ES ENTONCES PREDICHA EN BASE AL VALOR DE ÑAS O NIS QUE HA SIDO CALCULADO. LA INVENCIÓN TAMBIÉN COMPRENDE MÉTODOS PREDICTIVOS PARA LA RESPUESTA £ 15 CELULAR EN LOS CUALES EL CÁLCULO DE UN VALOR DE ÑAS O NIS PARA LAS CÉLULAS (POR EJEMPLO, LAS CÉLULAS TUMORALES) SE COMBINA CON EL USO DE UN ALGORITMO DE CLASIFICACIÓN ESTADÍSTICA. TAMBIÉN SE PROPORCIONAN BIOMARCADORES PARA PREDECIR LA RESPUESTA AL TRATAMIENTO CON UN AGENTE TERAPÉUTICO QUE DIRIGE UN COMPONENTE DENTRO DE LA VÍA DE SEÑALIZACIÓN ERBB
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18905308P | 2008-08-15 | 2008-08-15 | |
US19470208P | 2008-09-30 | 2008-09-30 | |
US20820609P | 2009-02-20 | 2009-02-20 | |
US17036709P | 2009-04-17 | 2009-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2011003840A true SV2011003840A (es) | 2011-07-06 |
Family
ID=41228727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2011003840A SV2011003840A (es) | 2008-08-15 | 2011-02-15 | Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar un paciente de acuerdo con la respuesta predicha |
Country Status (24)
Country | Link |
---|---|
US (4) | US8623592B2 (es) |
EP (1) | EP2318548B1 (es) |
JP (1) | JP2012500008A (es) |
KR (1) | KR20110044905A (es) |
CN (1) | CN102224255A (es) |
AU (1) | AU2009281721A1 (es) |
BR (1) | BRPI0917871A2 (es) |
CA (1) | CA2732658A1 (es) |
CO (1) | CO6341654A2 (es) |
CR (1) | CR20110128A (es) |
DO (1) | DOP2011000054A (es) |
EA (1) | EA022884B1 (es) |
EC (1) | ECSP11010872A (es) |
ES (1) | ES2433424T3 (es) |
HK (1) | HK1155782A1 (es) |
IL (1) | IL210865A (es) |
MA (1) | MA32630B1 (es) |
MX (1) | MX2011001764A (es) |
NZ (1) | NZ591137A (es) |
PE (1) | PE20120015A1 (es) |
SV (1) | SV2011003840A (es) |
UA (1) | UA104868C2 (es) |
WO (1) | WO2010019952A2 (es) |
ZA (1) | ZA201100921B (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2129396T1 (sl) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
CA2732658A1 (en) | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
JP5677972B2 (ja) * | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
MX2012007340A (es) | 2009-12-22 | 2012-08-01 | Roche Glycart Ag | Anticuerpos anti/her3 y usos de los mismos. |
US8895001B2 (en) * | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
US20110318336A1 (en) * | 2010-03-29 | 2011-12-29 | George Mason Intellectual Properties, Inc. | Identification and Treatment of Aggressive Lung Cancer Tumors |
SG185366A1 (en) | 2010-05-04 | 2012-12-28 | Merrimack Pharmaceuticals Inc | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
WO2011159904A1 (en) * | 2010-06-17 | 2011-12-22 | The Trustees Of The University Of Pennsylvania | Methods for predicting cellular signaling responses to combinatorial stimuli |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
DK2635604T3 (en) | 2010-11-01 | 2017-02-27 | Symphogen As | PAN-HER-ANTIBODY COMPOSITION |
JP6105491B2 (ja) | 2011-03-02 | 2017-03-29 | バーグ エルエルシー | 照合性細胞ベースのアッセイ及びその使用 |
CA2828075A1 (en) | 2011-03-11 | 2012-09-20 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
PL2699602T3 (pl) | 2011-04-19 | 2017-11-30 | Merrimack Pharmaceuticals, Inc. | Bispecyficzne przeciwciała anty-IGF-1R i anty-ErbB3 |
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
EP2530462A1 (en) * | 2011-06-03 | 2012-12-05 | Merrimack Pharmaceuticals, Inc. | Methods and kits for predicting tumor responses to antibodies against epidermal growth factor receptor (EGFR) and uses thereof |
AU2012294326A1 (en) * | 2011-08-10 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy |
AU2012316402B2 (en) | 2011-09-30 | 2017-04-20 | Regeneron Pharmaceuticals, Inc. | Anti-ErbB3 antibodies and uses thereof |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
US9828635B2 (en) * | 2011-10-06 | 2017-11-28 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
WO2013071058A1 (en) | 2011-11-09 | 2013-05-16 | The Uab Research Foundation | Her3 antibodies and uses thereof |
WO2013086619A1 (en) * | 2011-12-16 | 2013-06-20 | Critical Outcome Technologies Inc. | Programmable cell model for determining cancer treatments |
SG10201608234UA (en) | 2012-04-02 | 2016-11-29 | Berg Llc | Interrogatory cell-based assays and uses thereof |
EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
KR102320059B1 (ko) | 2012-06-13 | 2021-11-01 | 아스트라제네카 아베 | 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획 |
KR101430309B1 (ko) * | 2012-11-14 | 2014-08-13 | 이선우 | 바이오 3d 모델링 장치 |
PT3447069T (pt) * | 2012-11-21 | 2020-11-13 | Janssen Biotech Inc | Anticorpos biespecíficos de egfr/c-met |
US10489717B2 (en) | 2013-01-03 | 2019-11-26 | Aetna, Inc. | System and method for pharmacovigilance |
US11424040B2 (en) * | 2013-01-03 | 2022-08-23 | Aetna Inc. | System and method for pharmacovigilance |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
KR20140093347A (ko) * | 2013-01-15 | 2014-07-28 | 삼성전자주식회사 | 항 c-Met 항체 처리에 의해 부작용을 유발하는 유전자 및 이를 이용한 약물 스크리닝 방법 |
CN105848678A (zh) * | 2013-09-30 | 2016-08-10 | 第三共株式会社 | 核酸生物标志物及其用途 |
WO2015048802A2 (en) | 2013-09-30 | 2015-04-02 | Daiichi Sankyo Co., Ltd. | Protein biomarker and uses thereof |
EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
US20150285817A1 (en) * | 2014-04-08 | 2015-10-08 | Biodesix, Inc. | Method for treating and identifying lung cancer patients likely to benefit from EGFR inhibitor and a monoclonal antibody HGF inhibitor combination therapy |
MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
US10482385B2 (en) | 2014-09-11 | 2019-11-19 | Berg Llc | Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
CA2983008A1 (en) | 2015-04-17 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Combination treatments with seribantumab |
GB201508841D0 (en) * | 2015-05-22 | 2015-07-01 | Isis Innovation | Treatment |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
CA2989815A1 (en) * | 2015-06-15 | 2016-12-22 | Nantomics, Llc | Systems and methods for patient-specific prediction of drug responses from cell line genomics |
US11384399B2 (en) | 2015-09-29 | 2022-07-12 | Htg Molecular Diagnostics, Inc. | Methods for subtyping diffuse large B-cell lymphoma (DLBCL) |
MX2018011054A (es) | 2016-03-15 | 2019-01-21 | Merrimack Pharmaceuticals Inc | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. |
CN110168646B (zh) * | 2016-11-17 | 2023-12-19 | 南特生物科学公司 | 预测抗癌途径的验证 |
JP7404648B2 (ja) | 2019-04-25 | 2023-12-26 | 富士通株式会社 | 治療薬提示方法、治療薬提示装置、及び治療薬提示プログラム |
WO2021174210A1 (en) * | 2020-02-28 | 2021-09-02 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for determining spatial accumulation of signaling molecules within tissue samples |
WO2021240263A1 (en) | 2020-05-26 | 2021-12-02 | Insilico Medicine Ip Limited | Biological data signatures of aging and methods of determining a biological aging clock |
WO2022058980A1 (en) | 2020-09-21 | 2022-03-24 | Insilico Medicine Ip Limited | Methylation data signatures of aging and methods of determining a methylation aging clock |
CN113049249A (zh) * | 2020-12-31 | 2021-06-29 | 山东科技大学 | 一种电机轴承故障诊断方法及*** |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5344760A (en) | 1991-06-03 | 1994-09-06 | Ciba Corning Diagnostics Corp. | Method of cancer detection |
US6983227B1 (en) | 1995-01-17 | 2006-01-03 | Intertech Ventures, Ltd. | Virtual models of complex systems |
WO1997035885A1 (en) | 1996-03-27 | 1997-10-02 | Genentech, Inc. | ErbB3 ANTIBODIES |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
CA2258721C (en) | 1996-07-12 | 2014-09-09 | Genentech, Inc. | Chimeric heteromultimer adhesins |
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
US20020002276A1 (en) | 1997-02-10 | 2002-01-03 | Genentech, Inc. | Chimeric heteromultimer adhesins |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
GB2336695A (en) | 1998-04-20 | 1999-10-27 | Teamware Group Oy | Modelling a work process |
PL348634A1 (en) | 1998-05-15 | 2002-06-03 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
PT1210115E (pt) | 1999-08-27 | 2009-11-12 | Genentech Inc | Dosagens para tratamento com anticorpos anti-erbb2 |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
KR20030007640A (ko) | 2000-05-19 | 2003-01-23 | 제넨테크, 인크. | ErbB 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
US6871171B1 (en) | 2000-10-19 | 2005-03-22 | Optimata Ltd. | System and methods for optimized drug delivery and progression of diseased and normal cells |
EP1228766A1 (en) | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
WO2003011897A1 (en) | 2001-07-27 | 2003-02-13 | The Regents Of The University Of California | Modulation of heregulin and her3 interaction |
WO2003012072A2 (en) | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
EP1421113A4 (en) | 2001-08-03 | 2005-04-13 | Commw Scient Ind Res Org | SCREENING METHODS BASED ON CRYSTALLINE EGF RECEPTOR STRUCTURE |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
EP1435988A4 (en) | 2001-10-19 | 2008-01-09 | Pharmamar Sa | IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER |
US7415359B2 (en) | 2001-11-02 | 2008-08-19 | Gene Network Sciences, Inc. | Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents |
JP4660094B2 (ja) | 2002-03-26 | 2011-03-30 | ゼンサン (シャンハイ) サイ−テク. リミテッド | 新生物を治療するためのErbB3に基づく方法および組成物 |
US20040248151A1 (en) | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US20040229380A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
US20040132097A1 (en) | 2002-06-19 | 2004-07-08 | Bacus Sarah S. | Method for predicting response to epidermal growth factor receptor-directed therapy |
SI1517921T1 (sl) | 2002-06-28 | 2006-10-31 | Domantis Ltd | Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo |
BRPI0408928A (pt) * | 2003-04-01 | 2006-09-12 | Monogram Biosciences Inc | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
EP1651663B1 (en) | 2003-08-08 | 2017-05-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
WO2005017493A2 (en) | 2003-08-15 | 2005-02-24 | Smithkline Beecham Corporation | Biomarkers in cancer |
DE602004009817T2 (de) * | 2003-09-19 | 2008-08-21 | Nxp B.V. | Elektronische schaltung mit einem geheimen submodul |
US8554486B2 (en) | 2004-02-20 | 2013-10-08 | The Mathworks, Inc. | Method, computer program product, and apparatus for selective memory restoration of a simulation |
EP2439285B1 (en) | 2004-03-31 | 2019-05-08 | The General Hospital Corporation | Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments |
CA2565827A1 (en) | 2004-05-05 | 2005-12-15 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
CA2567293C (en) | 2004-05-27 | 2017-05-16 | The Regents Of The University Of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
WO2005121380A1 (en) | 2004-06-04 | 2005-12-22 | Smithkline Beecham Corporation | Predictive biomarkers in cancer therapy |
EP1807451A2 (en) | 2004-08-03 | 2007-07-18 | Dyax Corporation | Hk1-binding proteins |
ATE508753T1 (de) | 2004-08-06 | 2011-05-15 | Genentech Inc | Assays und verfahren unter verwendung von biomarkern |
CA2576886A1 (en) | 2004-08-12 | 2006-02-23 | Dyax Corp. | Tie complex binding proteins |
WO2006044378A2 (en) | 2004-10-12 | 2006-04-27 | University Of Iowa Research Foundation | Rapid computational identification of targets |
WO2006044748A2 (en) | 2004-10-15 | 2006-04-27 | Monogram Biosciences, Inc. | RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS |
GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
CN101163501A (zh) | 2005-02-23 | 2008-04-16 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
US20060204505A1 (en) | 2005-03-08 | 2006-09-14 | Sliwkowski Mark X | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
WO2007015935A2 (en) | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy |
WO2007041502A2 (en) | 2005-09-30 | 2007-04-12 | Monogram Biosciences | Methods for determining responsiveness to cancer therapy |
WO2007039705A1 (en) | 2005-10-05 | 2007-04-12 | Astrazeneca Uk Limited | Method to predict or monitor the response of a patient to an erbb receptor drug |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
WO2007109571A2 (en) | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
WO2007115571A2 (en) | 2006-04-07 | 2007-10-18 | Enkam Pharmaceuticals A/S | Erbb receptor-derived peptide fragments |
CA2650776A1 (en) | 2006-05-05 | 2007-11-15 | Yale University | Immunohistochemical methods for determining signal transduction activity in tumors |
CA2657324A1 (en) | 2006-07-13 | 2008-01-17 | Yale University | Methods for making cancer prognoses based on subcellular localization of biomarkers |
US20100047829A1 (en) | 2006-11-28 | 2010-02-25 | U3 Pharma Gmbh | Activated her3 as a marker for predicting therapeutic efficacy |
US7825127B2 (en) | 2006-12-28 | 2010-11-02 | Takeda Pharmaceutical Company, Limited | Method for treating cancer |
SI2129396T1 (sl) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
CL2008000614A1 (es) | 2007-03-02 | 2008-09-05 | Genentech Inc F Hoffmann La Ro | Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her. |
WO2008127710A2 (en) * | 2007-04-13 | 2008-10-23 | Dana Farber Cancer Institute | Methods for treating cancer resistant to erbb therapeutics |
CA2732658A1 (en) | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
-
2009
- 2009-08-17 CA CA2732658A patent/CA2732658A1/en not_active Abandoned
- 2009-08-17 MX MX2011001764A patent/MX2011001764A/es active IP Right Grant
- 2009-08-17 EA EA201100373A patent/EA022884B1/ru not_active IP Right Cessation
- 2009-08-17 UA UAA201101792A patent/UA104868C2/uk unknown
- 2009-08-17 KR KR1020117005954A patent/KR20110044905A/ko not_active Application Discontinuation
- 2009-08-17 BR BRPI0917871A patent/BRPI0917871A2/pt not_active IP Right Cessation
- 2009-08-17 CN CN2009801404673A patent/CN102224255A/zh active Pending
- 2009-08-17 WO PCT/US2009/054051 patent/WO2010019952A2/en active Application Filing
- 2009-08-17 AU AU2009281721A patent/AU2009281721A1/en not_active Abandoned
- 2009-08-17 ES ES09791584T patent/ES2433424T3/es active Active
- 2009-08-17 EP EP09791584.7A patent/EP2318548B1/en not_active Revoked
- 2009-08-17 US US13/058,687 patent/US8623592B2/en not_active Expired - Fee Related
- 2009-08-17 JP JP2011523216A patent/JP2012500008A/ja active Pending
- 2009-08-17 PE PE2011000159A patent/PE20120015A1/es not_active Application Discontinuation
- 2009-08-17 NZ NZ591137A patent/NZ591137A/xx not_active IP Right Cessation
-
2010
- 2010-02-17 US US12/707,521 patent/US20110027291A1/en not_active Abandoned
-
2011
- 2011-01-25 IL IL210865A patent/IL210865A/en not_active IP Right Cessation
- 2011-02-04 ZA ZA2011/00921A patent/ZA201100921B/en unknown
- 2011-02-14 DO DO2011000054A patent/DOP2011000054A/es unknown
- 2011-02-15 SV SV2011003840A patent/SV2011003840A/es unknown
- 2011-02-16 CO CO11018669A patent/CO6341654A2/es not_active Application Discontinuation
- 2011-03-04 EC EC2011010872A patent/ECSP11010872A/es unknown
- 2011-03-10 CR CR20110128A patent/CR20110128A/es unknown
- 2011-03-11 MA MA33695A patent/MA32630B1/fr unknown
- 2011-09-21 HK HK11109930.1A patent/HK1155782A1/xx not_active IP Right Cessation
-
2014
- 2014-01-06 US US14/148,379 patent/US20140127238A1/en not_active Abandoned
-
2016
- 2016-12-20 US US15/384,664 patent/US20170307631A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
UA104868C2 (uk) | 2014-03-25 |
JP2012500008A (ja) | 2012-01-05 |
IL210865A (en) | 2014-04-30 |
PE20120015A1 (es) | 2012-01-26 |
NZ591137A (en) | 2012-10-26 |
MX2011001764A (es) | 2011-05-19 |
WO2010019952A2 (en) | 2010-02-18 |
EP2318548A2 (en) | 2011-05-11 |
CA2732658A1 (en) | 2010-02-18 |
CO6341654A2 (es) | 2011-11-21 |
US20110027291A1 (en) | 2011-02-03 |
WO2010019952A3 (en) | 2010-06-24 |
IL210865A0 (en) | 2011-04-28 |
EP2318548B1 (en) | 2013-10-16 |
US8623592B2 (en) | 2014-01-07 |
CN102224255A (zh) | 2011-10-19 |
AU2009281721A1 (en) | 2010-02-18 |
MA32630B1 (fr) | 2011-09-01 |
EA201100373A1 (ru) | 2011-08-30 |
US20140127238A1 (en) | 2014-05-08 |
ECSP11010872A (es) | 2011-09-30 |
EA022884B1 (ru) | 2016-03-31 |
ES2433424T3 (es) | 2013-12-11 |
US20110159513A1 (en) | 2011-06-30 |
CR20110128A (es) | 2011-09-27 |
HK1155782A1 (en) | 2012-05-25 |
DOP2011000054A (es) | 2011-04-30 |
BRPI0917871A2 (pt) | 2017-06-20 |
KR20110044905A (ko) | 2011-05-02 |
ZA201100921B (en) | 2014-06-25 |
US20170307631A1 (en) | 2017-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2011003840A (es) | Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar un paciente de acuerdo con la respuesta predicha | |
ECSP23004573A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
CR9365A (es) | Compuestos y metodos para la inhibicion de la protein-cinasa raf | |
BR112015017174A2 (pt) | preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico | |
CO2020005116A2 (es) | Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr | |
UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
CL2017002184A1 (es) | Composición que comprende sialillactosa para usar en la mejora de las aptitudes de aprendizaje y la función de memoria. | |
CL2020001797A1 (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas. | |
CL2012000456A1 (es) | Metodo para determinar el potencial de desarrollos de un embrion humano que comprende medir uno o mas parametros celulares que comprende los tiempos de duracion de la citocinesis. | |
WO2016094904A8 (en) | Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients | |
TR201909582T4 (tr) | Pirimido[4,5-b]indol türevleri ve hematopoetik kök hücrelerinin ekspresyonunda bunlarin kullanimi. | |
BR112021010354A2 (pt) | Métodos para o tratamento usando terapia celular adotiva | |
UY35427A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
ECSP099823A (es) | Nuevos compuestos químicos | |
BR112017022355A2 (pt) | ?método de indução de reparo de tecido, de migração de células-tronco e de crescimento de vaso sanguíneo em um indivíduo que tem uma lesão de tecido ou um sistema de reparo de tecido comprometido? | |
AR030236A1 (es) | Moléculas similares a il-17 y usos de las mismas | |
UY32937A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
CL2008002368A1 (es) | Uso de gaboxadol para preparar un medicamento util en el tratamiento de la depresion en pacientes que tienen uno o mas marcadores inflamatorios elevados o anormales. | |
CO6440595A2 (es) | Ligandos peptoides para el aislamiento y el tratamiento de células t autoinmunes | |
MX2015012176A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
EA201792602A1 (ru) | Стволовые клетки плацентарного происхождения и их применение для восстановления регенеративного механизма, коррекции протеомных дефектов и продления жизни стареющих индивидуумов | |
CO6341617A2 (es) | 5-alquinil-pirimidinas | |
CO2017005624A2 (es) | Composiciones oftálmicas estabilizadas de omega 3 | |
CL2014002975A1 (es) | Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2. |